Concepts (173)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hematopoietic Stem Cell Transplantation | 49 | 2023 | 95 | 9.390 |
Why?
|
| Graft vs Host Disease | 18 | 2023 | 33 | 2.880 |
Why?
|
| Leukemia, Myeloid, Acute | 16 | 2023 | 46 | 2.850 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 6 | 2023 | 32 | 1.520 |
Why?
|
| Transplantation Conditioning | 20 | 2023 | 31 | 1.280 |
Why?
|
| Myelodysplastic Syndromes | 5 | 2022 | 29 | 0.930 |
Why?
|
| Hematologic Neoplasms | 2 | 2020 | 18 | 0.810 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 4 | 2023 | 13 | 0.760 |
Why?
|
| Transplantation, Homologous | 15 | 2023 | 248 | 0.730 |
Why?
|
| Humans | 61 | 2023 | 25692 | 0.720 |
Why?
|
| Hodgkin Disease | 4 | 2021 | 16 | 0.710 |
Why?
|
| Lymphoma, Non-Hodgkin | 4 | 2023 | 33 | 0.690 |
Why?
|
| Eye Diseases | 4 | 2019 | 7 | 0.640 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 6 | 2021 | 222 | 0.630 |
Why?
|
| Neoplasm Recurrence, Local | 9 | 2023 | 198 | 0.620 |
Why?
|
| Recurrence | 11 | 2023 | 275 | 0.570 |
Why?
|
| Retrospective Studies | 22 | 2023 | 3220 | 0.540 |
Why?
|
| Salvage Therapy | 3 | 2021 | 36 | 0.500 |
Why?
|
| Middle Aged | 25 | 2023 | 8403 | 0.500 |
Why?
|
| Adult | 24 | 2023 | 7336 | 0.470 |
Why?
|
| Cyclophosphamide | 6 | 2023 | 43 | 0.420 |
Why?
|
| Transplantation, Autologous | 7 | 2022 | 151 | 0.410 |
Why?
|
| Drug Resistance, Neoplasm | 4 | 2021 | 57 | 0.410 |
Why?
|
| Prognosis | 11 | 2023 | 739 | 0.400 |
Why?
|
| Primary Myelofibrosis | 2 | 2023 | 3 | 0.400 |
Why?
|
| Multiple Myeloma | 2 | 2022 | 18 | 0.390 |
Why?
|
| Disease-Free Survival | 9 | 2022 | 152 | 0.370 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 2 | 2021 | 14 | 0.360 |
Why?
|
| Male | 22 | 2022 | 13917 | 0.340 |
Why?
|
| Aged | 19 | 2023 | 8501 | 0.340 |
Why?
|
| Adolescent | 11 | 2023 | 2076 | 0.330 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 2 | 2020 | 9 | 0.330 |
Why?
|
| Calcineurin Inhibitors | 4 | 2023 | 14 | 0.320 |
Why?
|
| Allografts | 5 | 2021 | 203 | 0.310 |
Why?
|
| Young Adult | 11 | 2021 | 1855 | 0.310 |
Why?
|
| Female | 21 | 2023 | 14273 | 0.280 |
Why?
|
| Hemoglobin SC Disease | 1 | 2006 | 1 | 0.260 |
Why?
|
| Splenic Diseases | 1 | 2006 | 3 | 0.260 |
Why?
|
| Rituximab | 3 | 2023 | 45 | 0.260 |
Why?
|
| Chromosome Aberrations | 3 | 2021 | 9 | 0.250 |
Why?
|
| Survival Rate | 7 | 2021 | 308 | 0.250 |
Why?
|
| Immunosuppressive Agents | 3 | 2020 | 124 | 0.230 |
Why?
|
| Risk Factors | 5 | 2023 | 2224 | 0.220 |
Why?
|
| Scedosporium | 1 | 2023 | 4 | 0.220 |
Why?
|
| Bacterial Infections | 1 | 2023 | 41 | 0.220 |
Why?
|
| Quality of Life | 4 | 2022 | 600 | 0.220 |
Why?
|
| Leukemia, Myelomonocytic, Chronic | 1 | 2023 | 2 | 0.210 |
Why?
|
| POEMS Syndrome | 1 | 2022 | 1 | 0.200 |
Why?
|
| Unrelated Donors | 4 | 2023 | 5 | 0.200 |
Why?
|
| Autografts | 2 | 2019 | 28 | 0.200 |
Why?
|
| Bone Marrow | 4 | 2023 | 79 | 0.190 |
Why?
|
| Hypogonadism | 1 | 2021 | 7 | 0.190 |
Why?
|
| Infertility | 1 | 2021 | 8 | 0.190 |
Why?
|
| Heart Failure | 1 | 2023 | 166 | 0.190 |
Why?
|
| Testicular Neoplasms | 1 | 2021 | 19 | 0.190 |
Why?
|
| Bone Marrow Transplantation | 4 | 2023 | 22 | 0.190 |
Why?
|
| Cytomegalovirus | 1 | 2021 | 14 | 0.190 |
Why?
|
| Roseolovirus Infections | 1 | 2021 | 3 | 0.180 |
Why?
|
| Cord Blood Stem Cell Transplantation | 1 | 2021 | 5 | 0.180 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2021 | 17 | 0.180 |
Why?
|
| Siblings | 4 | 2022 | 14 | 0.180 |
Why?
|
| Cytomegalovirus Infections | 1 | 2021 | 28 | 0.180 |
Why?
|
| Stem Cell Transplantation | 2 | 2020 | 38 | 0.180 |
Why?
|
| Melphalan | 4 | 2021 | 5 | 0.180 |
Why?
|
| Core Binding Factor beta Subunit | 1 | 2020 | 2 | 0.180 |
Why?
|
| Oncogene Proteins, Fusion | 1 | 2020 | 10 | 0.180 |
Why?
|
| Return to Work | 1 | 2021 | 53 | 0.180 |
Why?
|
| Immunotherapy, Adoptive | 1 | 2020 | 4 | 0.180 |
Why?
|
| Myeloablative Agonists | 1 | 2020 | 1 | 0.180 |
Why?
|
| Calcineurin | 1 | 2020 | 8 | 0.180 |
Why?
|
| Cardiovascular Diseases | 1 | 2023 | 340 | 0.170 |
Why?
|
| Remission Induction | 4 | 2022 | 80 | 0.170 |
Why?
|
| Granulocyte Precursor Cells | 1 | 2019 | 3 | 0.170 |
Why?
|
| Survival Analysis | 4 | 2021 | 246 | 0.170 |
Why?
|
| Transplantation, Haploidentical | 1 | 2019 | 1 | 0.170 |
Why?
|
| Drug Resistance | 1 | 2019 | 37 | 0.160 |
Why?
|
| Steroids | 1 | 2019 | 23 | 0.160 |
Why?
|
| Neoplasms | 1 | 2022 | 224 | 0.160 |
Why?
|
| Typhlitis | 1 | 2019 | 2 | 0.160 |
Why?
|
| Mucositis | 1 | 2019 | 5 | 0.160 |
Why?
|
| Lymphoma, T-Cell | 1 | 2019 | 4 | 0.160 |
Why?
|
| Lung Diseases | 1 | 2019 | 42 | 0.160 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 77 | 0.160 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 80 | 0.160 |
Why?
|
| Liver Diseases | 1 | 2019 | 32 | 0.150 |
Why?
|
| Pandemics | 1 | 2020 | 227 | 0.150 |
Why?
|
| Lymphoma | 1 | 2017 | 30 | 0.150 |
Why?
|
| Lymphoma, B-Cell | 1 | 2017 | 8 | 0.140 |
Why?
|
| Vidarabine | 3 | 2022 | 8 | 0.140 |
Why?
|
| Cachexia | 1 | 2017 | 11 | 0.140 |
Why?
|
| Busulfan | 3 | 2021 | 3 | 0.140 |
Why?
|
| Child, Preschool | 3 | 2023 | 640 | 0.130 |
Why?
|
| Chronic Disease | 3 | 2023 | 403 | 0.120 |
Why?
|
| Activities of Daily Living | 1 | 2019 | 560 | 0.120 |
Why?
|
| Acute Disease | 2 | 2023 | 187 | 0.110 |
Why?
|
| Aged, 80 and over | 5 | 2020 | 4459 | 0.110 |
Why?
|
| Follow-Up Studies | 4 | 2021 | 1689 | 0.110 |
Why?
|
| Incidence | 3 | 2021 | 731 | 0.110 |
Why?
|
| Interleukin-2 | 1 | 2012 | 22 | 0.100 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2012 | 43 | 0.100 |
Why?
|
| Melanoma | 1 | 2012 | 52 | 0.100 |
Why?
|
| Kidney Neoplasms | 1 | 2012 | 70 | 0.100 |
Why?
|
| Treatment Outcome | 4 | 2020 | 3231 | 0.090 |
Why?
|
| Cohort Studies | 3 | 2022 | 1781 | 0.090 |
Why?
|
| Antineoplastic Agents | 1 | 2012 | 169 | 0.090 |
Why?
|
| Vincristine | 2 | 2023 | 17 | 0.090 |
Why?
|
| Tacrolimus | 2 | 2021 | 14 | 0.090 |
Why?
|
| Doxorubicin | 2 | 2023 | 47 | 0.090 |
Why?
|
| Prednisone | 2 | 2023 | 58 | 0.090 |
Why?
|
| Mutation | 2 | 2023 | 325 | 0.090 |
Why?
|
| Leukocyte Count | 2 | 2020 | 62 | 0.080 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2020 | 157 | 0.080 |
Why?
|
| Treatment Failure | 2 | 2020 | 154 | 0.080 |
Why?
|
| Cytarabine | 2 | 2020 | 11 | 0.080 |
Why?
|
| Etoposide | 2 | 2020 | 25 | 0.080 |
Why?
|
| Prospective Studies | 3 | 2020 | 1633 | 0.080 |
Why?
|
| Registries | 2 | 2020 | 170 | 0.080 |
Why?
|
| Multivariate Analysis | 2 | 2020 | 299 | 0.080 |
Why?
|
| Comorbidity | 2 | 2020 | 457 | 0.080 |
Why?
|
| Risk Assessment | 2 | 2021 | 618 | 0.070 |
Why?
|
| Pain | 2 | 2021 | 372 | 0.070 |
Why?
|
| Proportional Hazards Models | 2 | 2018 | 332 | 0.070 |
Why?
|
| Child | 2 | 2021 | 1277 | 0.070 |
Why?
|
| United States | 2 | 2023 | 1943 | 0.070 |
Why?
|
| Splenomegaly | 1 | 2006 | 6 | 0.070 |
Why?
|
| Erythropoiesis | 1 | 2006 | 5 | 0.070 |
Why?
|
| Splenectomy | 1 | 2006 | 7 | 0.070 |
Why?
|
| Abdominal Pain | 1 | 2006 | 8 | 0.070 |
Why?
|
| Fatal Outcome | 1 | 2006 | 51 | 0.060 |
Why?
|
| Fever | 1 | 2006 | 30 | 0.060 |
Why?
|
| Neoplasm Staging | 2 | 2019 | 315 | 0.060 |
Why?
|
| Toes | 1 | 2023 | 6 | 0.050 |
Why?
|
| Voriconazole | 1 | 2023 | 12 | 0.050 |
Why?
|
| Tissue Donors | 1 | 2023 | 61 | 0.050 |
Why?
|
| Antifungal Agents | 1 | 2023 | 43 | 0.050 |
Why?
|
| Transplant Recipients | 1 | 2022 | 20 | 0.050 |
Why?
|
| Fetal Blood | 1 | 2022 | 12 | 0.050 |
Why?
|
| Bortezomib | 1 | 2021 | 2 | 0.050 |
Why?
|
| Neoplasm, Residual | 1 | 2021 | 8 | 0.050 |
Why?
|
| Survivors | 1 | 2021 | 67 | 0.050 |
Why?
|
| Canada | 1 | 2020 | 48 | 0.040 |
Why?
|
| Cyclosporine | 1 | 2020 | 13 | 0.040 |
Why?
|
| Cell Count | 1 | 2020 | 66 | 0.040 |
Why?
|
| Lymphocyte Transfusion | 1 | 2020 | 1 | 0.040 |
Why?
|
| Carmustine | 1 | 2020 | 2 | 0.040 |
Why?
|
| Pyrazines | 1 | 2019 | 9 | 0.040 |
Why?
|
| Gastrointestinal Tract | 1 | 2020 | 49 | 0.040 |
Why?
|
| Aniline Compounds | 1 | 2019 | 31 | 0.040 |
Why?
|
| Cause of Death | 1 | 2020 | 63 | 0.040 |
Why?
|
| Lymphocytes | 1 | 2020 | 57 | 0.040 |
Why?
|
| Neoplasm Grading | 1 | 2019 | 40 | 0.040 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2020 | 45 | 0.040 |
Why?
|
| Standard of Care | 1 | 2019 | 12 | 0.040 |
Why?
|
| Blood Donors | 1 | 2019 | 4 | 0.040 |
Why?
|
| Disease Progression | 1 | 2022 | 664 | 0.040 |
Why?
|
| Betacoronavirus | 1 | 2020 | 65 | 0.040 |
Why?
|
| Alemtuzumab | 1 | 2018 | 5 | 0.040 |
Why?
|
| Europe | 1 | 2018 | 64 | 0.040 |
Why?
|
| Age Factors | 1 | 2020 | 716 | 0.040 |
Why?
|
| Societies, Medical | 1 | 2018 | 138 | 0.040 |
Why?
|
| Proto-Oncogene Proteins c-bcl-6 | 1 | 2017 | 3 | 0.040 |
Why?
|
| Proto-Oncogene Proteins c-myc | 1 | 2017 | 14 | 0.040 |
Why?
|
| Ifosfamide | 1 | 2017 | 13 | 0.040 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2017 | 18 | 0.040 |
Why?
|
| Mass Screening | 1 | 2018 | 168 | 0.040 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 1 | 2017 | 25 | 0.040 |
Why?
|
| Methotrexate | 1 | 2017 | 34 | 0.030 |
Why?
|
| Dexamethasone | 1 | 2017 | 34 | 0.030 |
Why?
|
| Patient Care Team | 1 | 2018 | 130 | 0.030 |
Why?
|
| Inflammation | 1 | 2018 | 261 | 0.030 |
Why?
|
| Biomarkers | 1 | 2019 | 554 | 0.030 |
Why?
|
| Weight Loss | 1 | 2017 | 105 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2012 | 325 | 0.020 |
Why?
|